Encapsulated cell biodelivery of NGF (ECB‐NGF) for AD therapy has implications from astroglial activation and amyloid‐beta toxicity: Nonhuman/Lead optimization studies. (7th December 2020)
- Record Type:
- Journal Article
- Title:
- Encapsulated cell biodelivery of NGF (ECB‐NGF) for AD therapy has implications from astroglial activation and amyloid‐beta toxicity: Nonhuman/Lead optimization studies. (7th December 2020)
- Main Title:
- Encapsulated cell biodelivery of NGF (ECB‐NGF) for AD therapy has implications from astroglial activation and amyloid‐beta toxicity
- Authors:
- Mitra, Sumonto
Turchetto, Silvia
Wahlberg, Lars
Linderoth, Bengt
Behbahani, Homira
Eriksdotter, Maria - Abstract:
- Abstract: Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by loss of cholinergic neurons in the basal forebrain (BFCN). Mature Nerve growth factor (mNGF) is required for the survival of BFCN's, but since it cannot cross blood‐brain barrier (BBB), its tissue targeted delivery via encapsulated cell biodelivery (ECB‐NGF) device has been envisaged as a potential therapeutic strategy. In our previous first‐in‐human studies, we observed some inter‐capsule differences in mNGF release among ECB‐NGF devices, when implanted in human AD patients. To address this issue, we pursued whether amyloid‐beta (Ab40/42 ) peptides directly or indirectly (by activating astroglial cells) can affect the NGF‐delivering (NGC‐0211) cells. Method: We tested direct or astrocyte‐mediated (indirect) effect of Ab40 and Ab42 on the NGC‐0211 cells in‐vitro . To study the astrocyte‐mediated effects of Ab peptides, human primary astrocytes were first incubated with Ab peptides and the conditioned medium was further transferred on NGC‐0211 cells. Effects on cell survival (flowcytometry), stress markers (spectrophotometric measurements), cell proliferation (immunocytochemistry) and NGF release (ELISA) were monitored. Result: We report that Ab‐peptides induced marginal effects on cell survival and NGF release upon direct and indirect stimulation. Astrocyte conditioned media partially modulated biochemical parameters. In both cases of stimulation method, cellAbstract: Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterised by loss of cholinergic neurons in the basal forebrain (BFCN). Mature Nerve growth factor (mNGF) is required for the survival of BFCN's, but since it cannot cross blood‐brain barrier (BBB), its tissue targeted delivery via encapsulated cell biodelivery (ECB‐NGF) device has been envisaged as a potential therapeutic strategy. In our previous first‐in‐human studies, we observed some inter‐capsule differences in mNGF release among ECB‐NGF devices, when implanted in human AD patients. To address this issue, we pursued whether amyloid‐beta (Ab40/42 ) peptides directly or indirectly (by activating astroglial cells) can affect the NGF‐delivering (NGC‐0211) cells. Method: We tested direct or astrocyte‐mediated (indirect) effect of Ab40 and Ab42 on the NGC‐0211 cells in‐vitro . To study the astrocyte‐mediated effects of Ab peptides, human primary astrocytes were first incubated with Ab peptides and the conditioned medium was further transferred on NGC‐0211 cells. Effects on cell survival (flowcytometry), stress markers (spectrophotometric measurements), cell proliferation (immunocytochemistry) and NGF release (ELISA) were monitored. Result: We report that Ab‐peptides induced marginal effects on cell survival and NGF release upon direct and indirect stimulation. Astrocyte conditioned media partially modulated biochemical parameters. In both cases of stimulation method, cell proliferative ability of NGC0211 cells was significantly hampered. Conclusion: Our data suggests that the survival of the NGC‐0211 cells is not affected by Ab peptides, whereas their proliferation was significantly hampered, directly as well as through astroglial activation. Overall, NGF release was not affected negatively under the conditions and time points tested in this study. This study lays the foundation for further optimization of ECB‐NGF devices for future AD therapy. … (more)
- Is Part Of:
- Alzheimer's & dementia. Volume 16(2020)Supplement 9
- Journal:
- Alzheimer's & dementia
- Issue:
- Volume 16(2020)Supplement 9
- Issue Display:
- Volume 16, Issue 9 (2020)
- Year:
- 2020
- Volume:
- 16
- Issue:
- 9
- Issue Sort Value:
- 2020-0016-0009-0000
- Page Start:
- n/a
- Page End:
- n/a
- Publication Date:
- 2020-12-07
- Subjects:
- Alzheimer's disease -- Periodicals
Alzheimer Disease -- Periodicals
Dementia -- Periodicals
Démence
Maladie d'Alzheimer
Périodique électronique (Descripteur de forme)
Ressource Internet (Descripteur de forme)
616.83 - Journal URLs:
- http://www.sciencedirect.com/science/journal/15525260 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1002/alz.045104 ↗
- Languages:
- English
- ISSNs:
- 1552-5260
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0806.255333
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 15114.xml